In 2025, sales are anticipated to grow by a high single-digit percentage at CER, previous view mid-to-high single-digit. Sanofi (SNY) confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER before share buyback, now including all expenses from newly acquired businesses. Sanofi intends to complete its EUR 5 billion share buyback program in 2025. 80.3% has been repurchased to date
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis Treatment?
- Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis
- Sanofi’s TZIELD® Study: A Potential Game-Changer for Type 1 Diabetes
- Regeneron and Sanofi’s Real-World Asthma Study: A Potential Game Changer
- Sanofi’s Riliprubart Study: A Potential Game-Changer for CIDP Treatment